A-674563 is a selective inhibitor of Akt1, a protein kinase that plays an important role in several cellular processes, including cell growth and survival. It has been extensively studied for its potential therapeutic applications in cancer and other diseases, and the chemical compound is known by its chemical name, 2-(4-(3-(5-chloro-2-hydroxyphenyl)-1H-pyrazol-4-ylamino)quinazolin-6-yl)oxy-N-methylacetamide.
The molecular formula of A-674563 is C23H20ClN5O3, and its formula weight is 459.9 g/mol. The compound is identified by its CAS number, 552325-73-2.
Top ten keywords from Google search related to A-674563 are:
Synonyms of A-674563 Akt1 Inhibitor include:
Health benefits of A-674563 Akt1 Inhibitor:
A-674563 is a promising drug candidate for various types of cancer treatment due to its ability to inhibit the activity of Akt1, a protein kinase that is frequently overexpressed or hyperactivated in many types of human cancer. Akt1 plays a critical role in several cellular processes, including cell growth, proliferation, survival, and metabolism, making it an attractive pharmacological target for cancer therapy.
Research has shown that inhibition of Akt1 can induce apoptosis (programmed cell death) in cancer cells, reduce chemotherapy resistance, and suppress metastatic potential. A-674563 has also been shown to sensitize cancer cells to radiation therapy, suggesting its potential use as a combination therapy with radiotherapy.
Potential effects of A-674563 Akt1 Inhibitor:
Preclinical studies have demonstrated the efficacy of A-674563 in inhibiting the growth of various cancer cell lines, including breast, lung, prostate, and ovarian cancer. In animal models of human cancer, A-674563 has shown significant antitumor activity, reducing tumor growth and increasing survival rates.
Product mechanism:
A-674563 inhibits the activity of Akt1 by binding to its ATP-binding site, preventing the phosphorylation of downstream targets involved in cell survival and proliferation. This results in the induction of apoptosis and suppression of tumor growth.
Safety:
Although A-674563 has shown promising preclinical anticancer activity, its safety and toxicity profile in humans are not fully understood. Further clinical trials are needed to evaluate its safety and potential side effects.
Side effects:
Common side effects associated with Akt inhibitors include nausea, vomiting, diarrhea, fatigue, and rash. However, the specific side effects of A-674563 have not been determined yet.
Dosing information:
The optimal dosing regimen for A-674563 in humans is not established yet. Preclinical studies have used doses ranging from 10-100 mg/kg, given orally or intraperitoneally. The appropriate dose and route of administration in humans will depend on several factors, including patient characteristics, cancer type, and stage of disease.
Conclusion:
A-674563 Akt1 Inhibitor is a promising drug candidate for cancer therapy due to its ability to selectively inhibit the activity of Akt1, a protein kinase that plays a critical role in cancer cell growth and survival. Although its safety and toxicity profile in humans are not fully understood, preclinical studies have shown significant antitumor activity in various cancer types. Further clinical trials are needed to establish its safety and efficacy as a cancer therapy
